烟草治疗项目对头颈鳞癌吸烟者戒烟率与生存率的影响
本研究回顾性评估了117例接受烟草治疗项目的当前吸烟p16阴性黏膜头颈鳞癌患者,比较戒断组与非戒断组的9个月7天点戒断率及生存结局。
要点
- 早期头颈鳞癌戒断者死亡风险显著低于继续吸烟者。
- 应重视头颈鳞癌患者烟草依赖治疗。
核心结论
- 烟草治疗项目在头颈鳞癌吸烟者中实现较高戒断率,戒断的早期患者生存更优。
研究设计与样本
- 回顾性队列研究,纳入117例当前吸烟的p16阴性黏膜头颈鳞癌患者,前瞻性入组烟草治疗项目。
主要发现
- 存活者中位随访62.4个月。
- 校正年龄、合并症和部位后,戒断的I-II期患者较吸烟的I-II期患者死亡风险降低(HR 0.15,95%CI 0.03-0.82)。
临床怎么用
- 对头颈鳞癌吸烟患者应实施烟草依赖治疗以促进戒断并可能改善早期患者生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately one quarter of head and neck cancer (HNC) patients smoke cigarettes at the time of diagnosis. Despite HNC guideline recommendations to treat tobacco dependence, the effectiveness of treatment in this population is poorly described. METHODS: This retrospective cohort review evaluated 117 current smokers with p16-negative mucosal head and neck squamous cell carcinoma prospectively enrolled in a tobacco treatment program. Seven-day point prevalence tobacco abstinence rates at 9 months and survival outcomes were compared among abstinent and nonabstinent groups. RESULTS: Median follow-up among survivors was 62.4 months. Forty percent of patients were abstinent at 9 months according to intention-to-treat analysis. After adjustment for age, comorbidity and site, abstinent stage I to II patients had a decreased risk of death compared to smoking stage I to II patients (HR 0.15, 95% CI 0.03-0.82). CONCLUSIONS: High cohort abstinence rates and favorable survival among abstinent patients with early-stage HNC confirm the importance of tobacco dependence treatment in this population.
引用
- Day AT, Dahlstrom KR, Lee R, et al. Impact of a tobacco treatment program on abstinence and survival rates among current smokers with head and neck squamous cell carcinoma. Head Neck. 2020. PMID: 32476217. doi:10.1002/hed.26268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。